24 recruiting, 15 completed, 12 active not recruiting, 7 unknown. 31 Phase 2, 18 Phase 3, 5 Not applicable, 4 Phase 1, 1 Phase 4.
Follow Endocrine Therapy: new trials by email Literature Review of Endocrine Therapy trials Research Report on Endocrine Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers Stereotactic Radiation Therapy, Endocrine Therapy - Breast Cancer, Early-Stage Breast Carcinoma | Not applicable | Not yet recruiting | Renaissance Institute of Precision Oncology and Radiosurgery | 30 | 2027-01-01 | 2026-09-28 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases Culmerciclib, Anlotinib, Endocrine Therapy - HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2026-08-28 | 2026-08-04 |
| Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study Upfront Breast Surgery, Adjuvant Radiotherapy, Endocrine Therapy - Lobular Breast Carcinoma | Recruiting | Istituto Oncologico Veneto IRCCS | 250 | 2026-05-01 | 2026-09-02 | |
| A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 40 | 2025-11-17 | 2026-11-02 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-09-24 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer Chemotherapy, CDK4/6 Inhibitor, Endocrine therapy - Breast Cancer, Adjuvant Therapy | Phase 3 | Not yet recruiting | Fudan University | 1244 | 2025-06-15 | 2025-06-05 |
| Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy - Breast Cancer | Phase 2 | Recruiting | Xijing Hospital | 27 | 2025-06-05 | 2026-08-14 |
| Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer Dalpicilib, endocrine therapy - Breast Cancer | Phase 3 | Recruiting | Fudan University | 1388 | 2025-01-09 | 2026-09-29 |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer Alisertib, Endocrine therapy - Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Puma Biotechnology, Inc. | 225 | 2024-11-19 | 2026-10-01 |
| Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer Endocrine therapy, Chemotherapy Prednisone - ESR1 Gene Mutation, Advanced Breast Cancer | Recruiting | SciClone Pharmaceuticals | 450 | 2024-08-08 | 2024-08-12 | |
| Pre-Operative Window of ET to Inform RT Decisions (POWER II) Tamoxifen, Letrozole, Anastrozole, or Exemestane - Breast Cancer Female | Phase 3 | Recruiting | University of Virginia | 354 | 2024-07-19 | 2026-06-30 |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers Endocrine Therapy, Biopsy of breast, Neratinib - Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2024-06-11 | 2026-08-19 |
| ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy - Breast Carcinoma | Phase 3 | Recruiting | Institut Curie | 300 | 2024-05-27 | 2026-04-17 |
| Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients CDK 4/6 inhibitors, Endocrine therapy - Metastatic Breast Cancer, Advanced Breast Cancer | Phase 3 | Recruiting | Region Örebro County | 495 | 2024-04-01 | 2024-11-19 |
| Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer Dalpiciclib, Endocrine therapy - Early Breast Cancer | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 1163 | 2023-11-17 | 2024-04-02 |
| Young Patients With Early Breast Cancer operation - Breast Cancer Female | Active not recruiting | Peking Union Medical College Hospital | 1000 | 2023-08-01 | 2025-08-03 | |
| Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors - Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Fudan University | 265 | 2023-07-26 | 2024-02-08 |
Showing 20 of 67. Sign in to see all of them.
Breast Neoplasms (48) · Carcinoma, Lobular (5) · Prostatic Neoplasms (4) · Carcinoma, Ductal, Breast (2) · Carcinoma, Intraductal, Noninfiltrating (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Neoplasms, Hormone-Dependent (2) · Brain Neoplasms (1) · Carcinoma, Islet Cell (1) · Epilepsy (1) · Gastrinoma (1) · Glucagonoma (1) · Insulinoma (1) · Lethal Congenital Contracture Syndrome 2 (1)
Fudan University (3) · Eli Lilly and Company (2) · Intarcia Therapeutics (2) · M.D. Anderson Cancer Center (2) · Peking Union Medical College Hospital (2) · SOLTI Breast Cancer Research Group (2) · SWOG Cancer Research Network (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Zhejiang Cancer Hospital (2) · Albert Einstein College of Medicine (1) · Asan Medical Center (1) · Bristol-Myers Squibb (1) · Burzynski Research Institute (1) · CCTU- Cancer Theme (1)
United States (29) · China (20) · Spain (10) · France (6) · United Kingdom (6) · Belgium (5) · Canada (5) · Germany (5) · Italy (5) · Japan (4) · Portugal (4) · Russia (4) · South Korea (4) · Australia (3) · Poland (3)
Shayna L Showalter, MD (2) · Aleix Prat, MD, PhD (1) · Amar Kishan (1) · Antonio Llombart, MD, PhD (1) · Antonios Valachis, Assoc Prof (1) · Arielle Medford, MD (1) · Bing-Shu Xia (1) · Brigitte Rack, MD (1) · Cesar A. Santa-Maria, MD, MSCI (1) · Charles D. Cobau, MD (1) · Charlotte E Coles, MB ChB, MRCP, FRCR, PhD (1) · Christos Sotiriou, MD (1)
PMID 38913933, PMID 20004966, PMID 24919854, PMID 27289552, PMID 28238593, PMID 29045543, PMID 30653209, PMID 32460816, PMID 33369581, PMID 34277393, PMID 34660302, PMID 35135810, PMID 35223458, PMID 36649570, PMID 37450351, PMID 38421243, PMID 39431459, PMID 39621968, PMID 39838117, PMID 39838118, PMID 40167440, PMID 40294349, PMID 40331570, PMID 40608342, PMID 40888443, PMID 41100122, PMID 41272386, PMID 41276768, PMID 41672025
2017 (3), 2023 (2), 2009 (1), 2014 (1), 2018 (1), 2019 (1), P30CA006973 (1), P30CA013330 (1), P30CA016672 (1), P30CA036727 (1), R01CA273246 (1), R21CA277311 (1), U10CA032102 (1), U10CA037403 (1), U10CA180868 (1)